Tests to predict tolerance to radiotherapy
Tests to predict tolerance to radiotherapy
PERSONALIZING CANCER TREATMENT
More than 50% of cancer patients will be treated with radiotherapy.
Nearly 10% of patients treated with radiotherapy will develop irreversible side effects.
Identifying these hypersensitive patients prior to treatment is key to personalizing each patient’s care pathway.
TESTS BASED ON A SIMPLE BLOOD SAMPLE
For prostate cancer
For breast cancer
WHY HAVE A NOVAGRAY TEST?
NovaGray tests assess a patient’s individual radiosensitivity. This is important information that can help:
- Reassure patients in preparation for radiotherapy
- Guide physicians in choosing the most appropriate treatment plan
- Adapt patient follow-up after radiotherapy
HOW TO PERFORM A TEST?
The test is performed before the start of radiotherapy.
OUR TESTS ARE RECOMMENDED BY THE FRENCH SOCIETY OF RADIATION ONCOLOGY
The NovaGray technology has been validated in multi-center prospective clinical studies. The NovaGray tests are recommended by the French Society of Radiation Oncology (SFRO).
